期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 377, 期 19, 页码 1813-1823出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1708539
关键词
-
资金
- GlaxoSmithKline
- Novartis
- National Institute for Health Research Biomedical Research Centre at the Royal Marsden NHS Foundation Trust
- Institute of Cancer Research
- Australian National Health and Medical Research Council fellowship
- University of Sydney Medical Foundation
- Amgen
- Array BioPharma
- Bristol-Myers Squibb
- Merck Sharp Dohme
- Pierre Fabre
- Roche
- Merck
- Provectus
- Merck Serono
- Philogen
- Regeneron
- OncoSec
- Pfizer
- Eisai
- Kymab
- Roche/Genentech
- Secarna
- EUSA Pharma
- Sysmex
- Boehringer Ingelheim
- Novartis/GlaxoSmithKline
- Teva
- Takeda
- Prometheus
- Genentech
- EMD Serono
BACKGROUND Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations to receive oral dabrafenib at a dose of 150 mg twice daily plus trametinib at a dose of 2 mg once daily (combination therapy, 438 patients) or two matched placebo tablets (432 patients) for 12 months. The primary end point was relapse-free survival. Secondary end points included overall survival, distant metastasis-free survival, freedom from relapse, and safety. RESULTS At a median follow-up of 2.8 years, the estimated 3-year rate of relapse-free survival was 58% in the combination-therapy group and 39% in the placebo group (hazard ratio for relapse or death, 0.47; 95% confidence interval [CI], 0.39 to 0.58; P<0.001). The 3-year overall survival rate was 86% in the combination-therapy group and 77% in the placebo group (hazard ratio for death, 0.57; 95% CI, 0.42 to 0.79; P = 0.0006), but this level of improvement did not cross the prespecified interim analysis boundary of P=0.000019. Rates of distant metastasis-free survival and freedom from relapse were also higher in the combination-therapy group than in the placebo group. The safety profile of dabrafenib plus trametinib was consistent with that observed with the combination in patients with metastatic melanoma. CONCLUSIONS Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvant use of placebo and was not associated with new toxic effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据